Cellulose Or Derivative Patents (Class 514/57)
-
Patent number: 8765715Abstract: A method of providing hemostasis of bleeding tissue. A flexible bioresorbable foam is formed that consists essentially of carboxymethylcellulose. The flexible bioresorbable foam is crosslinked. Chain scission is performed on the crosslinked flexible bioresorbable foam to provide the flexible bioresorbable foam with a selected in-vivo residence time of between about 3 days and about 14 days. Hemostasis is caused by applying the flexible bioresorbable foam to bleeding tissue. The flexible bioresorbable foam is resorbed in-vivo. The selected in-vivo residence time is a time between the flexible bioresorbable foam being applied to the tissue and the flexible bioresorbable foam having been substantially completely absorbed into the tissue.Type: GrantFiled: November 20, 2012Date of Patent: July 1, 2014Assignee: Medtronic, Inc.Inventors: Dana A. Oliver, Matthew J. Halversen, Aimee Hodge
-
Publication number: 20140171386Abstract: Compositions (including pharmaceutical compositions, foods, supplements, toys and treats) comprising a microbial exopolysaccharide are provided as well as methods for preventing or reducing diarrhea in a mammal wherein the method comprises administering a therapeutically amount of a microbial exopolysaccharide to a mammal in need thereof.Type: ApplicationFiled: February 24, 2014Publication date: June 19, 2014Applicant: Hill's Pet Nutrition, Inc.Inventors: Wai Lun Cheuk, Christina Khoo
-
Patent number: 8753658Abstract: A termite bait includes a plurality of cellulosic food material pieces palatable to termites embedded within a water resistant polyurethane foam matrix. Another termite bait includes a plurality of cellulosic food material pieces embedded within a water-absorbent polyurethane foam matrix. Yet another termite bait includes at least one cellulosic food material piece encapsulated within a water resistant polyurethane foam coating. Such termite baits can be used alone or in a monitoring device or other termite control device. Another termite control device includes a container, a cellulosic food material within the container and a water resistant polyurethane foam positioned to separate the food material from its environment. The container can contain a termite bait as described above or can include a chamber containing a cellulosic food material and at least one pocket containing a polyurethane foam barrier to reduce intrusion of water through the pocket to the food material.Type: GrantFiled: March 15, 2013Date of Patent: June 17, 2014Assignee: Dow AgroSciences, LLC.Inventors: Joseph Edward Eger, Jr., Donald E. Williams, III, Sol M. Mirasol, Mike P. Tolley, Joseph J. DeMark, Matthew T. Messenger, Phillip J. Howard
-
Publication number: 20140148407Abstract: The invention provides an aqueous gel comprising: a) from 0.5 to 5 wt % dispersed modified cellulose biopolymer, wherein the modification consists of the cellulose having its C6 primary alcohols oxidised to carboxyl moieties (acid/COOH—) on 10 to 70% of the glucose units and substantially all the remainder of the C6 positions occupied by unmodified primary alcohols; b) a water-soluble or water-miscible organic non-solvent for the modified cellulose biopolymer; c) 0 to 10 wt % non-surfactant electrolyte, and d) water; in which the aqueous gel comprises less than 3 wt % oil phase ingredients. The aqueous gels of the invention offer excellent tactile properties, in particular superior skin feel and reduced stickiness. Furthermore, the gels have thixotropic properties, allowing their usage in pumpable or sprayable formats. They also provide sufficient structure for the suspension of a variety of particulate materials.Type: ApplicationFiled: May 9, 2012Publication date: May 29, 2014Inventors: Janet Lesley Scott, Christopher Smith, Giovanni Francesco Unali
-
Patent number: 8729050Abstract: A method for treating or preventing disorders, diseases, and symptom of reflux, that is laryngopharyngeal reflux (LPR), in the laryngopharynx caused by pepsin comprises orally administering to the laryngopharynx of a patient an effective amount of cellulose powder. A method for treating or preventing damage to the lining membranes of at least some of the aerodigestive tract, the damage caused by pepsin, comprises coating at least some of the lining membranes with an effective amount of a cellulose powder. Upon inhalation of the powder, the powder coats the lining membranes. Upon coating the lining membranes, the powder becomes a gel. The gel prevents the pepsin from binding with the lining membranes, thereby preventing damage caused by pepsin in laryngopharyngeal reflux or in extra-esophageal reflux.Type: GrantFiled: October 7, 2009Date of Patent: May 20, 2014Assignee: Euphora Ltd.Inventors: Jamie Koufman, Michael James, Peter Josling
-
Publication number: 20140134217Abstract: The compositions and methods of this invention relate to a leave-on skin care composition containing hydrophobic, linear cellulose particles having an average length of from about 1 to about 500 ?m, a particle aspect ratio from about 2 to about 25 and an average thickness of from about 1 to about 500 ?m; and a cosmetically acceptable carrier.Type: ApplicationFiled: March 13, 2013Publication date: May 15, 2014Applicant: JOHNSON & JOHNSON CONSUMER COMPANIES, INC.Inventor: JOHNSON & JOHNSON CONSUMER COMPANIES, INC.
-
Publication number: 20140134218Abstract: The compositions and methods of this invention relate to a rinse-off skin care composition containing hydrophobic, linear cellulose particles having an average length of from about 1 to about 1000 ?m, a particle aspect ratio from about 1000 to about 2 and a thickness of from about 1 to about 500 ?m; at least one cleansing agent selected from the group consisting of a saponified fat and a surfactant; and a cosmetically acceptable carrier.Type: ApplicationFiled: March 13, 2013Publication date: May 15, 2014Applicant: JOHNSON & JOHNSON CONSUMER COMPANIES, INC.Inventor: JOHNSON & JOHNSON CONSUMER COMPANIes, inc.
-
Patent number: 8722081Abstract: A hemostatic textile material to stop bleeding comprising a dialdehyde cellulose (DAC) carrier wherein the degree of oxidation of the dialdehyde cellulose varies from about 1.5% to 12%; and a blood coagulation factor selected from the group consisting of chitosan and gelatin; the blood coagulation factor being chemically immobilized thereon; and further optionally comprising a bacteriolytic agent selected from the group consisting of a lysozyme enzyme, silver nitrate, and chlorhexidine; and further optionally comprising a selected component that prevents hemolysis, the component selected from the group consisting of tranexamic acid or ?-aminocaproic acid chemically immobilized thereon.Type: GrantFiled: October 15, 2007Date of Patent: May 13, 2014Inventors: Vladimir N. Filatov, Vladimir Ryltsev, Zidkiyahu Simenhaus
-
Publication number: 20140120169Abstract: A process for preparing polymeric composite particles includes the steps of preparing an oil phase containing a biodegradable polymer and a water phase containing a hydrophilic compound or nanoparticle and emulsifying the oil phase in the water phase to form emulsions. Then solvent is removed from the emulsions to prepare the particles in the form of capsules and spheres in sizes from 0.01 ?m (10 nm) to 50 ?m.Type: ApplicationFiled: October 24, 2013Publication date: May 1, 2014Applicant: Board of Trustees of Michigan State UniversityInventors: Ilsoon Lee, Shaowen Ji
-
Patent number: 8697125Abstract: The present invention provides a tablet without causing a tableting trouble, which is superior in the tablet formability, dissolution property of pharmaceutically active ingredient, and the like.Type: GrantFiled: January 30, 2008Date of Patent: April 15, 2014Assignee: Takeda Pharmaceutical Company LimitedInventors: Akihiko Ono, Shigeyuki Marunaka, Makoto Fukuta
-
Patent number: 8691974Abstract: A novel BC fermentation technique for controlling 3D shape, thickness and architecture of the entangled cellulose nano-fibril network is presented. The resultant nano-cellulose based structures are useful as biomedical implants and devices, are useful for tissue engineering and regenerative medicine, and for health care products. More particularly, embodiments of the present invention relate to systems and methods for the production and control of 3-D architecture and morphology of nano-cellulose biomaterials produced by bacteria using any biofabrication process, including the novel 3-D Bioprinting processes disclosed. Representative processes according to the invention involve control of the rate of production of biomaterial by bacteria achieved by meticulous control of the addition of fermentation media using a microfluidic system. In exemplary embodiments, the bacteria gradually grew up along the printed alginate structure that had been placed into the culture, incorporating it.Type: GrantFiled: September 28, 2010Date of Patent: April 8, 2014Assignee: Virginia Tech Intellectual Properties, Inc.Inventors: Paul Gatenholm, Henrik Backdahl, Theodore Jon Tzavaras, Rafael V. Davalos, Michael B. Sano
-
Publication number: 20140079663Abstract: The invention relates to inhibitory compounds of a p38 MAP kinase having a structure of type (I)-(VII) which can be used for the treatment or prophylaxis of adhesion. Pharmaceutical compositions are disclosed containing an effective amount of the substance SB203580 or one or more of the conjugated compounds of type (I)-(VII) or a combination thereof, and a pharmaceutically acceptable carrier, a diluent or an excipient. Also disclosed is the use of the substance SB203580 as an agent having anti-adhesion activity. Also disclosed is a method for the prophylaxis and/or treatment of a disease or a condition in which there is a possibility of the formation and/or growth of adhesions, which makes it possible to dispense with the additional administration of a preparation in the post-operative period.Type: ApplicationFiled: November 18, 2013Publication date: March 20, 2014Applicant: Joint Stock Company "Pharmasyntez"Inventors: Mikhail Gennadievich Shurygin, Irina Aleksandrovna Shurygina
-
Publication number: 20140076345Abstract: Provided is a cleansing composition for skin or hair capable of bringing about a good rinse feel and, in regard to hair, imparting softness to hair during rinsing and after towel drying, and further, imparting a sufficient moist feeling also to skin after application. A cleansing composition for skin or hair, comprising the following (A) and (B): (A) an internal olefin sulfonate having 12 or more and 24 or less carbon atoms; and (B) a cationic polymer or an amphoteric polymer.Type: ApplicationFiled: December 26, 2012Publication date: March 20, 2014Applicant: KAO CORPORATIONInventors: Ryosuke FUJII, Yasuhiro DOI
-
Publication number: 20140080786Abstract: The present invention provides a method for using processed-cellulose. Preferably, the processed cellulose is a highly refined cellulose (HRC). The HRC is useful in a number of medical and nutritional applications. These medical and nutritional applications can include, but are not limited to, administering effective amounts of the HRC for lowering values of risk factor measurements for such diseases as arteriosclerotic cardiovascular disease and diabetes. Treatment of other diseases and conditions with the HRC is also possible.Type: ApplicationFiled: November 22, 2013Publication date: March 20, 2014Applicant: Regents of the University of MinnesotaInventors: Paul Bradley Addis, Rongsheng Roger Ruan, Joseph M. Keenan, Daniela Geleva
-
Publication number: 20140072526Abstract: The present invention relates to an adsorbate of a pharmaceutically compatible rasagiline salt comprising at least one pharmaceutically compatible adjuvant, wherein the at least one pharmaceutically compatible adjuvant is a water-soluble, organic solvent and the rasagiline salt is present in the adsorbate as an amorphous substance.Type: ApplicationFiled: September 3, 2013Publication date: March 13, 2014Applicant: RATIOPHARM GMBHInventors: Alexander Lehmann, Frank Muskulus, Julia Schulze-Nahrup
-
Patent number: 8663678Abstract: A solid dosage form for the ocular administration of an active principle includes at least one biocompatible, water-soluble excipient for ophthalmic use. The form is obtained using a method which is selected from among the following: direct compression, dry compression, wet compression, compression of a lyophilizate, the compression being carried out a temperature below 45° C., or lyophilization, such that the form can disintegrate and release the active principle in the conjunctival sac. The invention also relates to an ophthalmic insert having the aforementioned dosage form which is appropriately dimensioned for ocular administration.Type: GrantFiled: December 17, 2002Date of Patent: March 4, 2014Assignee: Laboratoires TheaInventors: Saïd El Meski, Philippe Tourrette, Jean-Marc Aiache, Marie Di Battista, Gilbert Serpin
-
Publication number: 20140056980Abstract: In a delayed release formulation comprising a core containing a drug and a delayed release coating for providing intestinal release, release of the drug in the colon is accelerated by including an isolation layer between the core and the delayed release coating. The delayed release coating comprises an inner layer and an outer layer. The outer layer comprises a pH dependently soluble polymeric material which has a pH threshold at about pH 5 or above. The inner layer comprises a soluble polymeric material which is soluble in intestinal fluid or gastrointestinal fluid, said soluble polymeric material being selected from the group consisting of a polycarboxylic acid polymer that is at least partially neutralised, and a non-ionic polymer, provided that, where said soluble polymeric material is a non-ionic polymer, said inner layer comprises at least one additive selected from a buffer agent and a base.Type: ApplicationFiled: October 29, 2013Publication date: February 27, 2014Applicant: Tillotts Pharma AGInventors: Felipe José OLIVEIRA VARUM, Roberto Carlos Bravo González, Thomas Buser
-
Patent number: 8658621Abstract: A means is provided to make the capsules of cirrhotic or fibrotic livers relatively impermeable to liver tissue fluid or lymph in humans or other mammals suffering from severe chronic ascites or refractory ascites by application of collodion. The means will be useful to decrease the need for liver and combined liver and kidney transplantations.Type: GrantFiled: February 2, 2010Date of Patent: February 25, 2014Inventor: William Howard Waugh
-
Publication number: 20140045773Abstract: Ophthalmic compositions including compatible solute components and/or polyanionic components are useful in treating eyes, for example, to relieve dry eye syndrome, to protect the eyes against hypertonic insult and/or the adverse effects of cationic species on the ocular surfaces of eyes and/or to facilitate recovery from eye surgery.Type: ApplicationFiled: September 11, 2013Publication date: February 13, 2014Applicant: Allergan, Inc.Inventors: Joseph G. Vehige, Peter A. Simmons, Joan-En Chang-Lin
-
Publication number: 20140045761Abstract: Methods and devices for determining the healing status of wounds, in particular of chronic wounds are provided. Also provided are kits comprising the diagnostic devices, and methods of wound diagnosis and treatment using the diagnostic devices and methods. A diagnostic apparatus (device) for monitoring wounds that exude a wound fluid and determining whether said wounds would be responsive to treatment with wound therapy such as oxidized cellulose therapy is also provided along with kits comprising the diagnostic apparatus and a wound dressing. Furthermore, methods of prognosing and treating wounds that exude a wound fluid are also provided.Type: ApplicationFiled: January 31, 2012Publication date: February 13, 2014Applicant: Systagenix Wound Management IP CO. BVInventor: Molly Gibson
-
Publication number: 20140045785Abstract: The invention relates to use of microfibrillated cellulose as an anti-inflammatory agent for treatment of skin disorders.Type: ApplicationFiled: February 10, 2012Publication date: February 13, 2014Applicant: UPM-KYMMENE CORPORATIONInventors: Kaisa Herranen, Mia Lohman
-
Patent number: 8648065Abstract: An objective of the present invention is to provide a cefditoren pivoxil pharmaceutical preparation which can safely be administered to a patient and not only improves wettability of cefditoren pivoxil, but also further improves absorbability through the intestinal tracts by maintaining amorphous particles having a high oral absorbability in a liquid for a long period of time. The present invention is a pharmaceutical composition comprising amorphous cefditoren pivoxil and a sucrose fatty acid ester, which is obtainable by mixing or wet-granulating particles containing amorphous cefditoren pivoxil with the sucrose fatty acid ester while amorphous cefditoren pivoxil maintains its particle state.Type: GrantFiled: April 28, 2003Date of Patent: February 11, 2014Assignee: Meiji Seika Pharma Co., Ltd.Inventors: Yukiko Yokoi, Shigeru Chikase, Hiroyuki Yamaguchi
-
Patent number: 8637072Abstract: The present invention relates to wound dressings, in particular to an antibacterial wound dressing based on silvered gel-forming fabric and to a process for the manufacture of such a wound dressing.Type: GrantFiled: March 18, 2009Date of Patent: January 28, 2014Assignee: Convatec Technologies, Inc.Inventors: David Kershaw, Barry DeBoorder, Stephen John Law
-
Patent number: 8623840Abstract: The present invention provides a medicament or food supplement, that when ingested by an individual, forms a gel mass in the individual's stomach, said gel mass consisting essentially of methylcellulose and water, as well as methods for inducing satiety, reversibly reducing stomach void volume, and reducing caloric intake in an individual.Type: GrantFiled: April 27, 2011Date of Patent: January 7, 2014Assignee: Dow Global Tchnologies LLCInventors: Roland Adden, William H. Anderson, Britta Huebner, Matthias Knarr
-
Patent number: 8623841Abstract: The present invention provides a method for using processed-cellulose. Preferably, the processed cellulose is a highly refined cellulose (HRC). The HRC is useful in a number of medical and nutritional applications. These medical and nutritional applications can include, but are not limited to, administering effective amounts of the HRC for lowering values of risk factor measurements for such diseases as arteriosclerotic cardiovascular disease and diabetes. Treatment of other diseases and conditions with the HRC is also possible.Type: GrantFiled: August 24, 2011Date of Patent: January 7, 2014Assignee: Regents of the University of MinnesotaInventors: Paul Bradley Addis, Rongsheng Roger Ruan, Joseph M. Keenan, Daniela Geleva
-
Publication number: 20140005115Abstract: Provided herein are methods of treating, suppressing, inhibiting, or preventing bronchitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.Type: ApplicationFiled: March 7, 2013Publication date: January 2, 2014Applicant: YISSUM RESEARCH DEVELOPMENT COMPANYInventor: YISSUM RESEARCH DEVELOPMENT COMPAN
-
Publication number: 20130338058Abstract: In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis.Type: ApplicationFiled: January 9, 2013Publication date: December 19, 2013Applicant: YISSUM RESEARCH DEVELOPMENT COMPANYInventor: YISSUM RESEARCH DEVELOPMENT COMPANY
-
Patent number: 8603794Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: November 20, 2012Date of Patent: December 10, 2013Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Patent number: 8603793Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: May 30, 2012Date of Patent: December 10, 2013Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Publication number: 20130323183Abstract: The invention discloses pharmaceutical compositions in the form of a dusting powder or dry spray, possessing a high absorbent capacity, painkilling activity and wound-healing action, which compositions consist of croscarmellose sodium, a non-steroidal anti-inflammatory drug (NSAID) and hyaluronic acid, and optionally also contain other pharmacologically active substances and/or excipients. The compositions disclosed herein are suitable for use in the treatment of skin lesions wherein the presence of exudate limits wound healing and causes pain; they are therefore particularly suitable for chronic ulcerous skin lesions of various origins and burns.Type: ApplicationFiled: February 13, 2012Publication date: December 5, 2013Applicant: FIDIA FARMACEUTICI S.P.A.Inventors: Andrea Pastorello, Devis Galesso, Fabio Bettella
-
Publication number: 20130316974Abstract: The present invention is directed to hemostatic material containing compacted ORC powder comprising particles having an average aspect ratio from about 1 to about 18, wherein said compacted ORC powder have preferably been processed in a compaction device, such as a ball milled ORC powder. The present invention further relates to methods of making the hemostatic material and a method of treating a wound by applying the hemostatic powder onto and/or into the wound of a patient.Type: ApplicationFiled: May 25, 2012Publication date: November 28, 2013Inventors: Yi-Lan Wang, Guanghui Zhang
-
Publication number: 20130309266Abstract: The invention relates to compositions intended for reducing, ideally for eliminating, regurgitation and/or gastro-oesophageal reflux phenomena affecting a subject. Anti-regurgitation and/or anti-reflux infant formulas and milks intended for feeding newborn babies, infants and young children are more particularly described.Type: ApplicationFiled: December 16, 2011Publication date: November 21, 2013Applicant: UNITED PHARMACEUTICALSInventors: Jonathan Albert Margossian, Nicolas Pradeau, Yannick Fallourd
-
Patent number: 8580950Abstract: Novel aldehyde-functionalized polysaccharide compositions containing pendant dialdehyde groups are described that are more stable in aqueous solution than oxidized polysaccharides. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.Type: GrantFiled: December 21, 2010Date of Patent: November 12, 2013Assignee: Actamax Surgical Materials, LLCInventors: Helen S. M. Lu, Steven W. Shuey
-
Patent number: 8580951Abstract: Novel aldehyde-functionalized polysaccharide compositions are described that are more stable in aqueous solution than oxidized polysaccharides or other types of polysaccharides containing pendant aldehyde groups. The aldehyde-functionalized polysaccharides may be reacted with various amine-containing polymers to form hydrogel tissue adhesives and sealants that may be useful for medical applications such as wound closure, supplementing or replacing sutures or staples in internal surgical procedures such as intestinal anastomosis and vascular anastomosis, tissue repair, preventing leakage of fluids such as blood, bile, gastrointestinal fluid and cerebrospinal fluid, ophthalmic procedures, drug delivery, and preventing post-surgical adhesions.Type: GrantFiled: July 1, 2010Date of Patent: November 12, 2013Assignee: Actamax Surgical Materials, LLCInventors: Helen S. M. Lu, Steven W. Shuey
-
Patent number: 8580284Abstract: Abstract Provided is an oil-based cosmetic preparation which retains a smooth feel. Provided is an oil-based cosmetic preparation containing the following components (A), (B), and (C): (A) a cellulose derivative having a cellulose skeleton in a main chain, in which 67 mol % or more in total hydroxyl groups are substituted with a group —O-M-R, wherein M represents CH2 or a carbonyl group C?O, and R represents a straight or branched alkyl or alkenyl group having 3 to 40 carbon atoms; (B) an ester oil which is liquid at 25° C.; and (C) a hydrocarbon oil which is liquid at 25° C., in which a weight ratio (B)/(C) of the component (B) to the component (C) is 8/1 to 1/4.Type: GrantFiled: September 24, 2009Date of Patent: November 12, 2013Assignee: Kao CorporationInventors: Eiko Tamura, Kouji Ohsaki, Kazuo Kuwahara, Kazuhiro Ishikawa, Kenko Kurita, Yu Saito
-
Patent number: 8575108Abstract: A composition comprising from about 0.001% to about 0.4% cyclosporin A, a surfactant, and an oil having a specific gravity from 0.8 to 0.95 is disclosed herein.Type: GrantFiled: November 15, 2007Date of Patent: November 5, 2013Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Patent number: 8569263Abstract: A method of producing silane-modified cationized cellulose that has excellent aqueous dispersibility, including: a step (1) of cationizing water-soluble cellulose ether in a presence of alkali in a mixed solvent of a water-compatible organic solvent to obtain slurry comprising cationized cellulose; a step (2) of adding acid to said slurry and neutralizing said alkali; a step (3) of reacting said cationized cellulose obtained after said neutralization with an aminosilane compound and a step (4) of drying the obtained slurry, wherein: drying is conducted in step (4) at 115-160° C. until weight loss on drying is 5% by weight or less, or there is also including a step (5) of adding a water-compatible organic solvent or a mixed solvent of a water-compatible organic solvent and water to the cationized cellulose after the neutralization so that water content in a whole solvent that contacts the cationized cellulose is 10% by mass or less.Type: GrantFiled: August 22, 2008Date of Patent: October 29, 2013Assignee: LION CorporationInventors: Youichirou Kohno, Yoko Osako, Atsushi Ito
-
Patent number: 8569479Abstract: A process for reducing the average molecular weight of a cellulose ether comprises the step of contacting a cellulose ether with an acid to partially depolymerize it to a lower molecular weight in a diluent comprising at least 50 weight percent of an organic hydroxylic compound having at least one hydroxy group and at least two carbon atoms.Type: GrantFiled: April 23, 2007Date of Patent: October 29, 2013Assignee: Dow Global Technologies, LLCInventor: Charles B. Mallon
-
Patent number: 8563518Abstract: A composition is disclosed herein comprising from about 0.001% to about 0.Type: GrantFiled: June 28, 2012Date of Patent: October 22, 2013Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Publication number: 20130267478Abstract: There is disclosed a cosmetic comprises a sugar compound obtained by reacting a hydroxyl group of a saccharide, an isocyanate group-containing organopolysiloxane represented by the following general formula (1), and an isocyanate group-containing organic compound represented by the following general formula (2). As a result, there is provided a cosmetic excellent in cosmetic sustainability and storage stability that can improve such undesirable feelings of use as insufficient spreadability and stickiness, improve the solubility to not only a non-polar oil such as a silicone oil and a light liquid paraffin, but also a polar oil such as a UV-absorber, an ester oil, and a natural animal and vegetable oil, provides non-stickiness with a cosmetic containing the polar oil, and prevent adhesion of the cosmetic to clothes (secondary adhesion).Type: ApplicationFiled: March 21, 2013Publication date: October 10, 2013Applicant: SHIN-ETSU CHEMICAL CO., LTD.Inventor: Masanao KAMEI
-
Patent number: 8541392Abstract: The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the induced viscosity fiber system. Further, the invention relates to a method of incorporating soluble fiber into a liquid product without the typical negative organoleptic or physical stability issues. The invention also relates to a method of inducing the feeling of fullness and satiety by feeding the induced viscosity fiber system.Type: GrantFiled: September 30, 2009Date of Patent: September 24, 2013Assignee: Abbott LaboratoriesInventors: Bryan W. Wolf, Bruce B. Blidner, Keith A. Garleb, Chron-Si Lai, Timothy W. Schenz
-
Publication number: 20130244977Abstract: The present invention relates to a mask pack sheet using bio-cellulose obtained from fermented ginseng extracts, and more particularly, to a method for manufacturing a cosmetic mask pack sheet, comprising injecting microbial strains into a culture medium containing ginseng extracts so as to ferment the ginseng extracts and prepare a bio-cellulose sheet, and dipping the sheet into a cosmetic liquid.Type: ApplicationFiled: October 25, 2011Publication date: September 19, 2013Applicant: AMOREPACIFIC CORPORATIONInventors: Chang Keun Lee, Kuan Chi Hsu, Jun Cheol Cho, Youn Joon Kim, Sang Hoon Han
-
Publication number: 20130244978Abstract: The present invention provides an ophthalmic composition which stabilizes the tear film during wearing contact lens, prevents eye dryness, imparts a favorable sensation in using, is highly convenient with no risk of misuse and shows a high efficiency in the course from manufacturing to sales. More specifically, the present invention provides a wetting solution—eye drops for contact lenses or an ophthalmic composition/solution for contact lenses, which comprises (A) one or more member(s) selected from the group consisting of a cellulose-based polymer, a vinyl-based polymer, polyethylene glycol and dextran; and (B) a terpenoid.Type: ApplicationFiled: May 8, 2013Publication date: September 19, 2013Applicant: ROHTO PHARMACEUTICAL CO., LTD.Inventors: Yasuko MATSUMURA, Kazuhiro FUKUSHIMA
-
Publication number: 20130244976Abstract: The present invention provides a foam-type external skin preparation exhibiting an amount of and a retention of carbon dioxide foam appealing to the eye of the user, as well as good usability, such as in preventing the preparation from sagging from the skin, neither of which can be easily obtained with conventional foam-type external skin preparations. The present invention provides a foam-type external skin preparation containing a hydrophobically modified alkyl cellulose as an essential component.Type: ApplicationFiled: September 22, 2011Publication date: September 19, 2013Applicant: DAIDO CHEMICAL CORPORATIONInventors: Yasunari Inamoto, Toshio Shimamoto
-
Patent number: 8536134Abstract: A composition comprising a therapeutically effective amount of cyclosporin A, a blend of oils having a specific gravity of from 0.90 to 1.07, and a surfactant is disclosed herein.Type: GrantFiled: February 28, 2007Date of Patent: September 17, 2013Assignee: Allergan, Inc.Inventors: James N. Chang, Orest Olejnik, Bruce A. Firestone
-
Publication number: 20130217649Abstract: A wound dressing having anti-microbial activity comprises a first fibre capable of bonding with silver (1) cations. The wound dressing comprises a blend of the first fibre to which silver (1) cations are bonded and a second fibre which is substantially free from silver. The wound dressing comprises from 0.01 to 5.0 percent by weight of silver (1) cations, based on the weight of fibre.Type: ApplicationFiled: February 14, 2013Publication date: August 22, 2013Applicant: ConvaTec Technologies Inc.Inventor: ConvaTec Technologies Inc.
-
Publication number: 20130209444Abstract: The present invention provides non-anticoagulant sulfated or sulfonated polysaccharides (NASPs), which accelerate the blood clotting process. Also provided are pharmaceutical formulations comprising a NASP of the invention in conjunction with a pharmaceutically acceptable excipient and, in various embodiments, these formulations are unit dosage formulations. The invention provides a NASP formulation, which is orally bioavailable. Also provided are methods for utilizing the compounds and formulations of the invention to promote blood clotting in vivo as therapeutic and prophylactic agents and in vitro as an aid to studies of the blood clotting process.Type: ApplicationFiled: January 30, 2013Publication date: August 15, 2013Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Baxter International Inc., Baxter Healthcare S.A.
-
Patent number: 8507238Abstract: The present invention relates to polypeptides having cellobiohydrolase I activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides.Type: GrantFiled: October 8, 2012Date of Patent: August 13, 2013Assignee: Novozymes A/SInventors: Lene Lange, Wenping Wu, Dominique Aubert, Sara Landvik, Kirk Matthew Schnorr, Ib Groth Clausen
-
Patent number: 8507461Abstract: The present invention relates to compounds which are capable of exerting an inhibitory effect on the Na+ glucose cotransporter SGLT in order to hinder glucose and galactose absorption, as well as on lipase thus reducing dietary triglyceride metabolism, for use in the treatment of conditions which benefit therefrom (diabetes, Metabolic Syndrome, obesity, prevention of weight gain or aiding weight loss). These compounds comprise a non-absorbable, non-digestible polymer having a glucopyranosyl or galactopyranosyl or equivalent moiety stably and covalently linked thereto, said glucopyranosyl or galactopyranosyl moiety being able to occupy the glucose-binding pocket of a SGLT transporter.Type: GrantFiled: September 6, 2006Date of Patent: August 13, 2013Inventor: Abdalla Rifai
-
Publication number: 20130203699Abstract: A method of inhibiting the growth of bacteria in an absorbent device by using kraft pulp fiber subjected to an acidic, catalyzed peroxide treatment process incorporated into a single stage of a multi-stage bleaching process.Type: ApplicationFiled: March 14, 2013Publication date: August 8, 2013Applicant: GP Cellulose GMbHInventor: GP Cellulose GMbH